Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of remimazolam for moderate preoperative sedation in pediatric neurosurgery
ChiCTR2200067134Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in None, sponsored by Peking University First Hospital. Primary endpoint: ED90 of remimazolam for moderate sedation. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2200067134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067134.